Synairgen PLC (AIM:SNG, OTC:SYGGF)'s (Speymill Group (AIM:SYG)) chief executive Richard Marsden talks to Proactive following the release of the company's interim results.
Operationally, the company is using its SNG001 investigational formulation, with data gathered from a study of patients hospitalised with COVID, to look at a broader spectrum of respiratory conditions.